Victory Capital Management Inc Y M Abs Therapeutics, Inc. Transaction History

Victory Capital Management Inc

8 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2023 Nov 06, 2023	BUY	$4.86 - $7.23 $89,035 - $132,453	18,320 Added 20.09%	109,500 $596,000
Q2 2023 Jul 27, 2023	BUY	$5.68 - $10.34 $517,902 - $942,801	91,180 New	91,180 $619,000
Q3 2022 Nov 02, 2022	BUY	$13.96 - $19.67 $460,540 - $648,913	32,990 New	32,990 $476,000
Q2 2020 Aug 07, 2020	SELL	$23.66 - $49.53 $100,696 - $210,799	-4,256 Closed	0 $0
Q1 2020 May 04, 2020	SELL	$14.39 - $35.8 $14,908 - $37,088	-1,036 Reduced 19.58%	4,256 $111,000
Q4 2019 Feb 06, 2020	BUY	$23.81 - $33.78 $32,143 - $45,603	1,350 Added 34.25%	5,292 $165,000
Q4 2019 Feb 04, 2020	BUY	$23.81 - $33.78 $51,334 - $72,829	2,156 Added 120.72%	3,942 $130,000
Q3 2019 Nov 12, 2019	BUY	$21.57 - $31.37 $38,524 - $56,026	1,786 New	1,786 $47,000

106

24.5M

40.3K

400

Ticker YMAB
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 43,719,500
Market Cap $487M
Description
Y-mAbs Therapeutics, Inc., a commercial-stage biopharmaceutical company, focuses on the development and commercialization of novel antibody based therapeutic products for the treatment of cancer in the United States. It offers DANYELZA, a monoclonal antibody in combination with granulocyte-macrophage colony-stimulating factor for the treatment o...

Get notified when there are updates to the investment portfolio of Victory Capital Management Inc, based on Form 13F filings with the SEC.

Stay updated on Victory Capital Management Inc with notifications on news.